Format

Send to

Choose Destination
See comment in PubMed Commons below
Diabetes Res Clin Pract. 2012 Jul;97(1):27-42. doi: 10.1016/j.diabres.2011.12.015. Epub 2012 Jan 14.

An overview of the pharmacokinetics, efficacy and safety of liraglutide.

Author information

1
Atlanta Diabetes Associates, 77 Collier Rd, Suite 2080, Atlanta, GA 30309, USA. bbode001@aol.com

Abstract

OBJECTIVE:

Incretin-based therapies, including glucagon-like peptide 1 (GLP-1) receptor agonists, are the latest addition to the range of available medications for the management of patients with type 2 diabetes. The GLP-1 analog liraglutide has been approved for use in Europe and the US for over a year and has undergone evaluation in several pharmacokinetic/pharmacodynamics studies and in an extensive phase 3 clinical program. The aim of this review is to assess the pharmacokinetics, efficacy and safety of the phase 3 data.

METHODS:

Data are presented from the pharmacokinetics/pharmacodynamics studies of liraglutide and from nine published phase 3 studies, including the six Liraglutide Effect and Action in Diabetes (LEAD) studies.

RESULTS:

Liraglutide is effective at improving indices of glycemic control, and has a good tolerability and safety profile. Beneficial effects on weight (mean reduction of 1-3.4 kg) and blood pressure (systolic blood pressure decreased by 2.1-6.7 mmHg) are also observed.

CONCLUSION:

Liraglutide is an effective and well tolerated option for the treatment of type 2 diabetes.

PMID:
22245694
DOI:
10.1016/j.diabres.2011.12.015
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center